There are also some novel therapeutic strategies, such as using Ab@Tf-Cou6-PLGA NPs as intracellular transporters of antibodies to degrade BCR/ABL oncoproteins in CML cells [7]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.